456 related articles for article (PubMed ID: 20862981)
1. Radiolabeled somatostatin analogs for radionuclide imaging and therapy in patients with gastroenteropancreatic neuroendocrine tumors.
Bal CS; Gupta SK; Zaknun JJ
Trop Gastroenterol; 2010; 31(2):87-95. PubMed ID: 20862981
[TBL] [Abstract][Full Text] [Related]
2. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.
Teunissen JJ; Kwekkeboom DJ; Valkema R; Krenning EP
Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S27-51. PubMed ID: 22005114
[TBL] [Abstract][Full Text] [Related]
3. Molecular imaging as in vivo molecular pathology for gastroenteropancreatic neuroendocrine tumors: implications for follow-up after therapy.
Krenning EP; Valkema R; Kwekkeboom DJ; de Herder WW; van Eijck CH; de Jong M; Pauwels S; Reubi JC
J Nucl Med; 2005 Jan; 46 Suppl 1():76S-82S. PubMed ID: 15653655
[TBL] [Abstract][Full Text] [Related]
4. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.
Kwekkeboom DJ; Mueller-Brand J; Paganelli G; Anthony LB; Pauwels S; Kvols LK; O'dorisio TM; Valkema R; Bodei L; Chinol M; Maecke HR; Krenning EP
J Nucl Med; 2005 Jan; 46 Suppl 1():62S-6S. PubMed ID: 15653653
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; de Herder WW; Krenning EP
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):173-85, ix. PubMed ID: 21349418
[TBL] [Abstract][Full Text] [Related]
6. Radiolabeled somatostaitin analogs in the treatment of neuroendocrine tumors: experience of the National Cancer Institute of Milano using high dose of 111In-pentetreotide in metastatic neuroendocrine gastroenteropancreatic tumors.
Bombardieri E; Seregni E; Savelli G; Villano C; Castellani MR; Cirillo F; Pallotti F; Fracassi S; Chiesa C; Chiti A; Bajetta E
J Endocrinol Invest; 2003; 26(8 Suppl):63-9. PubMed ID: 15233216
[No Abstract] [Full Text] [Related]
7. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
Kaltsas GA; Papadogias D; Makras P; Grossman AB
Endocr Relat Cancer; 2005 Dec; 12(4):683-99. PubMed ID: 16322317
[TBL] [Abstract][Full Text] [Related]
8. [Imaging of somatostatin receptors in gastroenteropancreatic neuroendocrine tumors].
Mure A; Lebtahi R; de Labriolle-Vaylet C; Askienazy S
Gastroenterol Clin Biol; 1998 Oct; 22(10):809-18. PubMed ID: 9854206
[No Abstract] [Full Text] [Related]
9. Tumor imaging and therapy using radiolabeled somatostatin analogues.
de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
[TBL] [Abstract][Full Text] [Related]
11. Targeted radiotherapy with radiolabeled somatostatin analogs.
Nicolas G; Giovacchini G; Müller-Brand J; Forrer F
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):187-204, ix-x. PubMed ID: 21349419
[TBL] [Abstract][Full Text] [Related]
12. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate.
Kwekkeboom DJ; Bakker WH; Kam BL; Teunissen JJ; Kooij PP; de Herder WW; Feelders RA; van Eijck CH; de Jong M; Srinivasan A; Erion JL; Krenning EP
Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):417-22. PubMed ID: 12634971
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management.
Jamar F; Fiasse R; Leners N; Pauwels S
J Nucl Med; 1995 Apr; 36(4):542-9. PubMed ID: 7699439
[TBL] [Abstract][Full Text] [Related]
14. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies.
Anthony LB; Woltering EA; Espenan GD; Cronin MD; Maloney TJ; McCarthy KE
Semin Nucl Med; 2002 Apr; 32(2):123-32. PubMed ID: 11965607
[TBL] [Abstract][Full Text] [Related]
15. Neuroendocrine tumor imaging with 68Ga-DOTA-NOC: physiologic and benign variants.
Kagna O; Pirmisashvili N; Tshori S; Freedman N; Israel O; Krausz Y
AJR Am J Roentgenol; 2014 Dec; 203(6):1317-23. PubMed ID: 25415711
[TBL] [Abstract][Full Text] [Related]
16. Gamma Emitters in Pancreatic Endocrine Tumors Imaging in the PET Era: Is there a Clinical Space for 99mTc-peptides?
Briganti V; Cuccurullo V; Di Stasio GD; Mansi L
Curr Radiopharm; 2019; 12(2):156-170. PubMed ID: 30827276
[TBL] [Abstract][Full Text] [Related]
17. Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours.
Oberg K; Eriksson B
Best Pract Res Clin Endocrinol Metab; 2005 Jun; 19(2):265-76. PubMed ID: 15763700
[TBL] [Abstract][Full Text] [Related]
18. In situ radiotherapy with 111In-pentetreotide: initial observations and future directions.
McCarthy KE; Woltering EA; Espenan GD; Cronin M; Maloney TJ; Anthony LB
Cancer J Sci Am; 1998; 4(2):94-102. PubMed ID: 9532411
[TBL] [Abstract][Full Text] [Related]
19. Radiopharmaceuticals used for diagnosis and therapy of NETs.
Papachristou M
Hell J Nucl Med; 2023; 26 Suppl():19-20. PubMed ID: 37658556
[TBL] [Abstract][Full Text] [Related]
20.
Das S; Al-Toubah T; El-Haddad G; Strosberg J
Expert Rev Gastroenterol Hepatol; 2019 Nov; 13(11):1023-1031. PubMed ID: 31652074
[No Abstract] [Full Text] [Related]
[Next] [New Search]